Ketamine Alcohol (in Treatment-Resistant Depression)

This open-label, non-randomised study enrols treatment-resistant major depressive disorder patients to test whether a family history of alcohol use disorder predicts enhanced antidepressant response to a single subanesthetic ketamine infusion administered during 7T MRI (rs-fMRI and MRS).

Primary outcome is change in MADRS from baseline to 7 days post-infusion; secondary outcomes include vmPFC/vACC glutamate change and acute safety/tolerability measures.